Metastasectomy was initially described in the 1970s as a therapeutic strategy for patients with metastatic renal cell carcinoma.Since that time,systemic therapy options have grown exponentially,most recently with the ...Metastasectomy was initially described in the 1970s as a therapeutic strategy for patients with metastatic renal cell carcinoma.Since that time,systemic therapy options have grown exponentially,most recently with the introduction of immunotherapy.We aimed to review the contemporary literature regarding the role of metastasectomy in the era of targeted therapy and immunotherapy.Historically,metastasectomy has benefited patients with small volume,single-organ metastases,with favorable outcomes amongst younger,healthier patients with metastases to specific sites.The interplay between the employment of metastasectomy and systemic therapy has been limited to small,retrospective series with significant patient selection bias.More recently,investigators have conducted randomized controlled trials exploring the use of targeted therapies in the adjuvant setting after metastasectomy.Initial randomized data suggested no benefit in using sorafenib in this setting,and a subsequent study demonstrated possible harm in using pazopanib after metastasectomy.However,the role of other novel systemic therapies,including immunotherapy,nor the timing of use,have been meaningfully explored.Metastasectomy appears to be a valuable therapeutic option in the properly selected patient,requiring a multi-disciplinary management strategy and,pending future trials,a multimodal treatment approach.展开更多
文摘Metastasectomy was initially described in the 1970s as a therapeutic strategy for patients with metastatic renal cell carcinoma.Since that time,systemic therapy options have grown exponentially,most recently with the introduction of immunotherapy.We aimed to review the contemporary literature regarding the role of metastasectomy in the era of targeted therapy and immunotherapy.Historically,metastasectomy has benefited patients with small volume,single-organ metastases,with favorable outcomes amongst younger,healthier patients with metastases to specific sites.The interplay between the employment of metastasectomy and systemic therapy has been limited to small,retrospective series with significant patient selection bias.More recently,investigators have conducted randomized controlled trials exploring the use of targeted therapies in the adjuvant setting after metastasectomy.Initial randomized data suggested no benefit in using sorafenib in this setting,and a subsequent study demonstrated possible harm in using pazopanib after metastasectomy.However,the role of other novel systemic therapies,including immunotherapy,nor the timing of use,have been meaningfully explored.Metastasectomy appears to be a valuable therapeutic option in the properly selected patient,requiring a multi-disciplinary management strategy and,pending future trials,a multimodal treatment approach.
